Bionano Genomics (Nasdaq: BNGO) highlighted three peer-reviewed studies published in September 2026 that examined the clinical utility of its optical genome mapping (OGM) technology in myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and therapy-related myeloid neoplasms (t-MN).

The first study, from MD Anderson Cancer Center and published in Modern Pathology, analyzed 332 MDS samples and identified chromoanagenesis — a form of catastrophic genomic restructuring — in 15.9% of cases. Patients positive for the condition had a median overall survival of 9.9 months, compared with a median that was not reached in those without it.

The second study, from the University of Oulu and published in the International Journal of Cancer, examined 48 AML samples that appeared normal under standard karyotyping. OGM detected clinically relevant structural variants in 46% of those cases, and patients with OGM-detected abnormalities had significantly worse overall survival than those without (p = 0.005).

The third study, from the Josep Carreras Leukaemia Research Institute in Spain and published in npj Precision Oncology, applied OGM to 48 therapy-related myeloid neoplasm samples and 65 younger-onset MDS samples. OGM was interpretable in 100% of samples, including eight cases where conventional analysis failed, and identified 134 additional genomic alterations. Chromoanagenesis was the strongest independent predictor of inferior survival in multivariable analysis, with a hazard ratio of 9.26. Integrating OGM findings shifted 16.7% of t-MN and up to 12.8% of younger MDS patients into higher-risk categories.

"A meaningful fraction of high-risk genomic complexity in myeloid malignancies is simply invisible to conventional karyotyping," said Al Luderer, PhD, chairman and interim chief executive officer of Bionano, in a statement based on the press release.

Bionano notes its products are for research use only and not for use in diagnostic procedures.